BRPI0502497A - uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças - Google Patents

uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças

Info

Publication number
BRPI0502497A
BRPI0502497A BRPI0502497-8A BRPI0502497A BRPI0502497A BR PI0502497 A BRPI0502497 A BR PI0502497A BR PI0502497 A BRPI0502497 A BR PI0502497A BR PI0502497 A BRPI0502497 A BR PI0502497A
Authority
BR
Brazil
Prior art keywords
antagonists
protein
apoptotic activity
coupled receptor
receptor agonists
Prior art date
Application number
BRPI0502497-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Robson Augusto Souza Do Santos
Sergio Veloso Brant Pinheiro
Raphael De Faria E Silva
Ivana Silva Lula
Frederico Barros De Sousa
Frederico Jean Georges Frezard
Adelina Martha Dos Reis
Luiz Renato De Franca
Anderson Jose Ferreira
Ruben Dario Sinisterra
Maria Jose Campagnole-Santos
Walkyria Neyde De Oliv Sampaio
Marcelo De Castro Leal
Lenice Kappes Becker
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BRPI0502497-8A priority Critical patent/BRPI0502497A/pt
Priority to CNA2006800302306A priority patent/CN101247818A/zh
Priority to JP2008518575A priority patent/JP2008546811A/ja
Priority to PCT/BR2006/000125 priority patent/WO2007000036A2/en
Priority to CA002613126A priority patent/CA2613126A1/en
Priority to US11/922,949 priority patent/US20080312129A1/en
Priority to EP06741348A priority patent/EP1904087A2/en
Publication of BRPI0502497A publication Critical patent/BRPI0502497A/pt
Priority to JP2013000248A priority patent/JP2013075911A/ja
Priority to JP2017036611A priority patent/JP2017114901A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0502497-8A 2005-06-28 2005-06-28 uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças BRPI0502497A (pt)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0502497-8A BRPI0502497A (pt) 2005-06-28 2005-06-28 uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
CNA2006800302306A CN101247818A (zh) 2005-06-28 2006-06-28 Mas g-蛋白偶联受体激动剂和拮抗剂作为凋亡活性调节剂用于预防和治疗疾病的用途
JP2008518575A JP2008546811A (ja) 2005-06-28 2006-06-28 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用
PCT/BR2006/000125 WO2007000036A2 (en) 2005-06-28 2006-06-28 Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases
CA002613126A CA2613126A1 (en) 2005-06-28 2006-06-28 Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases
US11/922,949 US20080312129A1 (en) 2005-06-28 2006-06-28 Use of Mas G-Protein-Coupled Receptor Agonists and Antagonists, as Apoptotic-Activity Modulators for Study, Prevention and Treatment of Diseases
EP06741348A EP1904087A2 (en) 2005-06-28 2006-06-28 Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases
JP2013000248A JP2013075911A (ja) 2005-06-28 2013-01-04 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用
JP2017036611A JP2017114901A (ja) 2005-06-28 2017-02-28 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓ ｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0502497-8A BRPI0502497A (pt) 2005-06-28 2005-06-28 uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças

Publications (1)

Publication Number Publication Date
BRPI0502497A true BRPI0502497A (pt) 2007-02-06

Family

ID=37595483

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0502497-8A BRPI0502497A (pt) 2005-06-28 2005-06-28 uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças

Country Status (7)

Country Link
US (1) US20080312129A1 (https=)
EP (1) EP1904087A2 (https=)
JP (3) JP2008546811A (https=)
CN (1) CN101247818A (https=)
BR (1) BRPI0502497A (https=)
CA (1) CA2613126A1 (https=)
WO (1) WO2007000036A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113207799A (zh) * 2021-03-19 2021-08-06 中山大学 一种二型糖尿病小鼠快速心衰模型的构建方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0602366B1 (pt) 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
WO2008052295A1 (en) * 2006-10-30 2008-05-08 Universidade Federal De Minas Gerais Process for the preparation of compounds of at1 receptor antagonists with angiotensin-(1-7), analogues thereof and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products
EP2124991B1 (en) 2007-01-26 2013-11-27 Universidade Federal De Minas Gerais - UFMG Pharmaceutical compositions and methods for treating erectile dysfunction
BRPI0800585B8 (pt) 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
EP2163259B1 (en) 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury
DE102009013456A1 (de) * 2009-03-18 2010-09-23 GÖPFERICH, Achim, Prof. Dr. Nanopartikel für die Erkennung von Zellen, durch Bindung an G-Protein gekoppelte Rezeptoren
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
AU2013216910A1 (en) * 2012-02-10 2014-08-28 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
BR132012028005E2 (pt) * 2012-10-31 2014-11-18 Univ Minas Gerais Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares.
JP6254692B2 (ja) 2013-07-03 2017-12-27 ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ 認知機能不全を治療するための方法
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
JP6666899B2 (ja) 2014-07-21 2020-03-18 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
EP4371556A1 (en) 2022-11-15 2024-05-22 Explicat Pharma GmbH Angiotensin(1-7) pharmaceutical compositions for inhalation
CN116355856A (zh) * 2023-04-19 2023-06-30 陕西慧康生物科技有限责任公司 一种人mas1过表达细胞株及其构建方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6548302B1 (en) * 1998-06-18 2003-04-15 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6236766B1 (en) * 1998-09-11 2001-05-22 General Electric Company Method and apparatus for zooming digital images
CA2335391A1 (en) * 1998-10-02 2000-04-13 Kenneth Walsh Akt compositions for enhancing survival of cells
JP2002527489A (ja) * 1998-10-22 2002-08-27 キュラゲン コーポレイション 腎疾患および関連疾患に対する予想および治療的遺伝子およびタンパク質
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
CA2373693A1 (en) * 1999-05-20 2000-11-30 Human Genome Sciences, Inc. Seven transmembrane receptor genes
WO2001073033A2 (en) * 2000-03-29 2001-10-04 Beth Israel Deaconess Medical Center, Inc. Anti-angiogenic and anti-tumor properties of matin and other laminin domains
JP2003532623A (ja) * 2000-06-30 2003-11-05 バイエル アクチェンゲゼルシャフト 抗脈管形成性アンジオテンシン−７およびそれをコードするポリヌクレオチドを使用することによる脈管形成の調節方法
ATE320005T1 (de) * 2000-12-22 2006-03-15 Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
WO2006005470A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
BRPI0503122A (pt) * 2005-05-30 2007-05-02 Univ Minas Gerais composições farmacêuticas do peptìdeo angiotensina-(1-7) [ang-(1-7)] e seus análogos, agonistas e antagonistas usando as ciclodextrinas, seus derivados, e o polìmeros biodegradáveis e/ou dos produtos derivados para uso no controle das funções do sistema reprodutivo

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113207799A (zh) * 2021-03-19 2021-08-06 中山大学 一种二型糖尿病小鼠快速心衰模型的构建方法

Also Published As

Publication number Publication date
WO2007000036A2 (en) 2007-01-04
CA2613126A1 (en) 2007-01-04
CN101247818A (zh) 2008-08-20
EP1904087A2 (en) 2008-04-02
JP2008546811A (ja) 2008-12-25
WO2007000036A3 (en) 2007-05-18
JP2017114901A (ja) 2017-06-29
JP2013075911A (ja) 2013-04-25
US20080312129A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
BRPI0502497A (pt) uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
Recchia et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro
BRPI0414062A (pt) uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv
BR0314052A (pt) Imidazolpiridinas e métodos para sua fabricação e uso
BR0210886A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
UY38742A (es) Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
BR0313397A (pt) Inibidores de proteina cinase e usos destes
BRPI0610321B8 (pt) imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
CO6270277A2 (es) Anticuerpos especificos para la forma de protofibrillas de la proteina beta-amiloide
BR112014019776A2 (pt) composições e métodos para o tratamento de doença vascular periférica
BR112012020557A2 (pt) formas cristalinas de sódio 4- {[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido [5,4-d] [2] benzazepin-2-il]-amino}-2 metoxibenzoato de sódio.
CR9957A (es) Uso de un anatagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
GT200800265A (es) Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas.
SV2008002511A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
DOP2002000429A (es) Imidazotriazinas
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
BRPI0518105A (pt) uso de antagonista da angiogênese e uso de anticorpo anti-vegf
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
AR057239A1 (es) Inmunoglobulinas
Conte et al. Thymosin β4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B12F Other appeals [chapter 12.6 patent gazette]
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2476 DE 19/06/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2580 DE 16/06/2020 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: NAO HOUVE MANIFESTACAO AO 7.1 (RPI 2635, 06/07/21). ASSIM, INDEFIRO O PEDIDO, CF ART.25 DA LPI (LEI 9279/96).

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL